Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.

Woods-Swafford W, Vnencak-Jones CL, Loken MR, Manes B, Frangoul H
Pediatr Blood Cancer. 2008 50 (3): 639-41

PMID: 16927371 · DOI:10.1002/pbc.21017

Chronic myelogenous leukemia (CML) is rare in the pediatric population. Allogeneic stem cell transplant remains the only curative therapy; however, identifying a fully matched donor is not always possible. Imatinib mesylate has been shown to induce hematologic and cytogenetic response in adults and children with CML. We describe a child who achieved molecular remission with imatinib mesylate. BCR-ABL negative peripheral blood stem cells (PBSC) were successfully collected after mobilization with filgrastim.

(c) 2007 Wiley-Liss, Inc.

MeSH Terms (22)

Antineoplastic Agents Benzamides Biomarkers, Tumor Bone Marrow Purging Child Filgrastim Forecasting Fusion Proteins, bcr-abl Granulocyte Colony-Stimulating Factor Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cells Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid, Chronic-Phase Male Peripheral Blood Stem Cell Transplantation Piperazines Protein Kinase Inhibitors Pyrimidines Recombinant Proteins Remission Induction

Connections (1)

This publication is referenced by other Labnodes entities: